Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00154232
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00154388
Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00149903
- Locations
- 🇨🇳
General Hospital, Friendship Hospital, Beijing, No 1 Hospital Peking University, Beijing China; Shanghai No 1 Hospital, Shanghai China; Changzheng Hospital, Shanghai, China; Shanghai Ruij, Beijing, China
Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT00150046
- Locations
- 🇨🇭
Basel Novartis Pharma AG, Basel, Switzerland
🇩🇪Novartis Investigational Site, Germany, Germany
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT00149994
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of Imatinib in Chordoma
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00150072
- Locations
- 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00149981
- Locations
- 🇬🇧
Novartis Investigative Site, Salford, United Kingdom
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT00149916
Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT00150007
Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1869
- Registration Number
- NCT00142298
- Locations
- 🇬🇧
Novartis Investigational Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath